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ABSTRACT 
 
To survive in competitive market and to be successful, it is necessary to achieve high level of product quality 
Validation is one of the important steps in achieving and maintaining the quality of the final product batch after 
batch. Without equipment, we cannot manufacture a product. By validating each step of production process we can 
assure that the final product is of best quality. This review provides information on objectives and benefits of 
process validation, types of process validation, major phases in validation and regulatory aspects. 
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Introduction 
 
Validation is a systematic approach to identifying, 
measuring, evaluating, documenting and re-evaluating 
a series of critical step, in the manufacturing process 
that requires control to ensure a reproducible final 
product. It has become a necessary step to ensure better 
quality of medicinal product, throughout 
manufacturing, storage, handling and distribution. 
Quality cannot be inspected or tested into finished 
product. Thereby each step must be controlled to 
maximize probability that finished products meet all 
specifications. Process Validation is establishing 
documented evidence which provides a high degree of 
assurance that a specific process will consistently 
produce a product meeting its pre-determined 
specifications and Quality Standards.[1] 
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Process Validation has now become a part of Current 
Good Manufacturing Practices Regulations (cGMP), it 
is mandatory for manufacturers to go through Process 
Validation much more rigorously than earlier. Process 
Validation ensures improved levels of quality which 
inturn is bound to lead to reduced production costs by 
way of prevention of product failures. Thus Process 
validation also can be seen as a sound business 
proposition. By careful design and validation of both 
the process and process controls that a manufacturer 
can establish a high degree of confidence that all 
manufactured units from successive lots will be 
acceptable. Successfully validating a process may 
reduce the dependence upon intensive in-process and 
finished product testing.[2]  
 The FDA Guidelines on General Principles of Process 
Validation defines process validation as-“establishing 
documented evidence which provides a high degree of 
assurance that a specific process will consistently 
produce a product meeting its predetermined 
specifications and quality characteristics” 
According to EMEA, “Process validation can be 
defined as documented evidence that the process, 
operated within established parameters, can perform 
effectively and reproducibly to produce a medical 
product meeting its predetermined specifications and 
quality attributes”[3]Considering the case of tablets, 
Tablets may be swallowed whole or being chewed. 
Some are dissolved or dispersed in water before 
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administration. Some are put in oral cavity, where the 
active ingredient is liberated at a predetermined rate. 
Implants or passeries may also be presented in form of 
tablet. Tablet may vary in shape and differ greatly in 
size and weight depending on the amount of medicinal 
substance and the intended mode of administration. 
Objectives of process validation 
• To introduce software verification and 
validation and to discuss the distinction 
between them. 
• To describe the program inspection process 
and its role in V & V. 
• To explain static analysis as a verification 
technique. 
• To describe the Clean room software 
development process.[4] 
 
Importance of process validation 
• Government regulation 
• Rapid automation 
• Improved employee awareness 
• Easier maintenance of equipments 
• Increased output 
• Reduction in quality cost 
• Less failures of process thus less complaints 
• Process optimization[5] 
 
Types of process validation 
Prospective validation 
I. Establishing documented evidence prior to 
process implementation that a system does 
what it proposed to do based on preplanned 
protocols. 
II. This approach to validation is normally 
undertaken whenever the process for a new 
formula (or within a new facility) must be 
validated before routine pharmaceutical 
production commences.  
III. Validation of a process by this approach often 
leads to transfer of the manufacturing process 
from the development function to production. 
Retrospective validation 
I. Retrospective validation is used for facilities, 
processes, and process controls in operation 
use that have not undergone a formally 
documented validation process.  
II. Validation of these facilities, processes, and 
process controls is possible using historical 
data to provide the necessary documentary 
evidence that the process is doing what it is 
believed to do.  
III. This type of validation is only acceptable for 
well-established processes and will be 
inappropriate where there have been recent 
changes in the composition of product, 
operating processes, or equipment. 
Concurrent validation 
I. Concurrent validation is used for establishing 
documented evidence that a facility and 
processes do what they purport to do, based 
on information generated during actual 
imputation of the process.  
II. This approach involves monitoring of critical 
processing steps and end product testing of 
current production, to show that the 
manufacturing process is in a state of control. 
 
Revalidation 
I. Revalidation means repeating the original 
validation effort or any part of it, and includes 
investigative review of existing performance 
data.  
II. This approach is essential to maintain the 
validated status of the plant, equipment, 
manufacturing processes and computer 
systems. Possible reasons for starting the 
revalidation process include: 
• The transfer of a product from one plant to 
another. 
• Changes to the product, the plant, the 
manufacturing process, the cleaning process, 
or other changes that could affect product 
quality. 
• The necessity of periodic checking of the 
validation results. 
• Significant (usually order of magnitude) 
increase or decrease in batch size. 
• Sequential batches that fail to meet product 
and process specifications. 
• The scope of revalidation procedures depends 
on the extent of the changes and the effect 
upon the product. 
Strategy for industrial process validation of solid 
dosage forms  
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The following points gives strategy for process 
validation:  
• The use of different lots of raw materials 
should be included. i.e., active drug substance 
and major excipients.  
• Batches should be run in succession and on 
different days and shifts.  
• Batches should be manufactured in the 
equipment and facilities designated for 
eventual commercial production. 
• Critical process variables should be set within 
their operating ranges and should not exceed 
their upper and lower control limits during 
process operation. Output responses should be 
well within finished product specifications. [8] 
 
Guidelines for process validation of tablets 
There are several important reasons for validating a 
product and /or process. 
• Manufacturers are required by law to confirm 
to GMP regulations.  
• Good business dictates that a manufacture 
avoid the possibility of rejected or recalled 
batches. 
• Validation helps to ensure product uniformity, 
reproductibility, and quality. 
Process overview  
Dispensing 
Sifting 
Granulation 
Drying and sizing 
Lubrication, Compression 
                                             In process checking, packing, final product analysis and release 
Dispensing 
I. Ensure dispensing booth is clean and line check 
is given as per Standard operating procedure.  
II. Ensure that balance is not due for calibrated. 
Check for zero error in the balance.  
III. Check and ensure that the expire date of product 
to be released is later than that of batch expiry 
date.  
IV. Check and ensure that the all materials are 
issued as per Batch Processing Report.  
Sifting 
I. Check and record the temperature and relative 
humidity in processing area  i.e. 25 ±20° C & 
RH 45±5%.  
II. Check and ensure visually all the equipment 
and equipment parts are cleaned.  
III. Check and record the integrity of the sieves 
before and after sifting through out the 
processing activity.  
Granulation 
I. Add and dissolve ingredient into vessel.  
II. Add the other ingredients into mixer and mix 
for 5 minutes using impeller at slow speed.  
III. Collect, samples at 3,5 and 7 minutes at 5 
different places and analyze it for uniformity 
in content.  
IV. Add granulating solution and homogenize at 
slow speed for about 10 minutes.  
V. Check the Loss of drying in the wet granules.  
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Table1: Shows control parameters for granulation process 
Control Parameters  
Fixed  Variable (Monitor)  Response (Test)  
Equipment  Mixing speeds  
Amount of granulation  
Fluid feed rate granulation  
Time Load  
Drug distribution  
Water/ solvent  
Appearance (size)  
Power consumption (amp/torque)  
 
Drying and sizing 
Table 2: Shows control parameters for drying and sizing 
Fixed  Variable (Monitor)  Response (Test)  
Bowl charge  Inlet/ exhaust air 
temperature  
Particle size distribution  
Porosity of filter bags  Product temperature  Densities  
Bowl sieve  Drying time  Loss on drying  
   
Air volume  
Humidity of incoming air 
(dew point)  
Humidity of exhaust air  
Assay (for heat sensitive 
materials)  
 
I. Check and ensure the integrity of the 
Fluidized bed drying bag.  
II. Initially dry the wet granules with air for 10 
minutes.  
III. Check the Loss of drying of granules; it 
should not be not more than 1% at 70°C for 
15 minutes.   
IV. Check and ensure the dried granules are not 
stored above 25°C before the milling is 
started.  
V. Check and ensure the integrity of the sieves 
before and after sieving.  
VI. Pass the granules through 16 mm mesh sieve, 
break the oversize granules using mill fitted 
with 2mm screen.  
VII. Collect the granules and analyse their flow 
properties  
VIII. Check the weight of sifted and dried granules.  
 
Milling 
Table 3: Shows control parameters for milling 
Variable  
   
Response  
   
Screen size  
Milling speed  
Feed rate  
      Particle size distribution  
      Loose/ tapped densities  
 
Powder blending 
Table4: Shows control parameters for powder blending 
Variable  
   
Response  
Blending time  
Blender speed  
Intensifier bar  
Content uniformity  
Assay  
Particle size distribution  
Powder flow  
   
 
Lubrications 
Table 5: Shows control parameters for lubrications 
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Variable  Response  
Blending speed      
Blending time  
Method of addition  
Particle size distribution  
Loose / tapped densities  
Flow properties  
Tabletting characteristics  
 (Friability, hardness)  
 
I. Perform the pre mixing and final mixing as 
per Batch process report instruction  
II. During the final mixing before i.e., before 
adding the remaining quantity of the  lubricant 
mix for 15 minutes.  
III. Collects sample at 5,10,15 minute's intervals 
form top, middle, bottom and   
IV. Composite and subject it to analysis for assay.  
V. After adding the remaining quantity of 
lubricant mix for 5 minutes.  
VI. Collects sample at 3,5,7 minutes interval form 
top, middle, bottom and  composite and 
subject it to analysis for assay and content 
uniformity.  
VII. Check the weight of the final blend and 
record.  
 
Compression 
I. Check and ensure the temperature and relative 
humidity of the compression room  is not 
more than 25°C and Relative Humidity not 
more than 50%.  
II. Check and ensure the compression machine is 
cleaned. 
III. Collect 40 tablets and inspect for Appearance, 
weight, thickness, friability and hardness 
every 1 hour. 
IV. Tablets weight variation shall be XX mg. 
hardness shall be (IP) kg/cm2, thickness.  
V. Collect 40 tablets by "Bracketign" i.e. by 
increasing this speed of the compression 
machine form the target speed and by 
reducing from the targeted speed.  
VI. Collect 10 tablets during initial, middle and 
end of the compression process and  
subjective it to analysis for content uniformity 
and perform the assay also.  
 
Coating 
I. Check and ensure the coating pan and other 
equipment's are cleaned.  
II. Check and ensure that the tablets is deducted, 
the speed of the coating   pan inlet and exhaust 
air temperature, spray rate, spray type, 
temperature of the coating solution.  
III. After   coating   is   completed, samples   are   
collected   for dissolution testing and weight 
variation.  
 
Labelling and packing 
I. Check and record the temperature air the 
heating roller and sealing roller Check and 
record that the over printing instructions on 
labels and cartons.  
II. Check and verify that price overprinted on 
label and carton is as per current price list.  
III. After ensuring the proper labeling of tablets, 
check, for correctness of cartons packing for 
the same.  
 
Finished product analysis and release 
Finished product needs to be analyzed as per in-house 
specification product released only after predetermined 
specifications and quality attributes. Needs to be 
released only after pre-determined specifications [9-
12]As a means of providing a broad overview of these 
validation criteria, the following checklist/guideline. 
 Check list of Validation and Control Documentation[13] 
Table 6: Shows Check list of Validation and Control Documentation 
Sr. No. Selection of cGMP Validation and control documentation 
1 Introduction Establishing of QA & PV functions 
2 Organization and personnel. Establishment and facility installation and 
qualification 
3 Buildings and facilities Plant and facility installation qualification 
Maintenance and sanitation 
Microbial and pest control 
4 Equipment Installation and qualification cleaning methods. 
5 Air and water quality Water treatment and steam systems air, heat, 
and vacuum handling. 
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6 Control of raw material, in-process 
material, product 
Incoming components  
Manufacturing non-sterile products  
7 Production and process controls Process control systems (instruments and 
computers) 
8 Packing and labeling controls Depyrogenation, sterile packing, filling, and 
closing.  
9 Holding and distribution Facilities 
10 Laboratory controls Analytical methods  
11 Records and reports Computer systems  
12 Returned and salvage drug products  Batch processing 
 
Protocol for process validation 
Protocol for title page in industry is shown in table 7 [14] 
Table 7: Shows Check list of Validation and Control Documentation 
                                          NAME OF THE COMPANY 
                                 PROCESS VALIDATION PROTOCOL 
Product: Page no.:1 of 
Protocol no: Version no: 
Product name:  
Label claim:  
Master Formula Record no:  
Effective date:  
 
Protocol approval is shown in table 8 below:[15] 
Table 8: Shows Protocol approval 
 Prepared by                        Checked by Approved by 
Signature      
Date      
Name      
Department QA/R&D R&D Production QC Head QA 
 
Table of contents is shown in table 9 [16] 
Table 9: Shows Table of contents 
S.No. Title Page No. 
1 Protocol approval sheet  
2 Table of contents  
3 objective  
4 scope  
5 Validation term and responsibility  
6 Steps for validation and acceptance 
criteria 
 
7 Process flow chart  
8 Procedure  
9 Form – A : Review of raw 
material/packing material 
 
10 Form – B : Evaluation of active raw 
material 
 
11 Form – C : Evaluation of inactive 
raw material 
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12 Form – D : Qualification of 
equipment  
 
 
13 Form – E : Test instrument 
calibration  
 
14 Form – F : Dry mixing   
15 Sampling point diagram of RMG   
16 Form G-Wet mixing  
17 Form – H : Drying  
18 Sampling point diagram of FBD  
19 Form – I : Lubrication  
20 Sampling point diagram of RMG  
21 Form – J : Compression  
22 Form – K : Coating  
23 Form – L : Bulk packing  
24 Re validation criteria   
25 Change control  
26 Stability  
27 Deviations  
28 Conclusion  
29 Report and Approval  
 
8. Steps for validation and acceptance criteria in wet granulation process [4] 
The steps for acceptance criteria are summarized in table 10: 
Table 10: Shows Steps for validation and acceptance criteria in wet granulation process 
Sr. 
No 
Steps  Control Variable Critical Parameters  
to be checked 
Acceptance criteria 
1  Dry mixing  Time …. Mixing time and  
speed 
Mixing time: ………………min.  
Impeller speed: (slow/medium/high) ± 
5RPM.  
Content uniformity :90%-110%  
RSD : ±5% 
Impeller speed.   
2  Binder 
preparation 
and addition 
Time  Mode and time of  
addition 
Depending up on the formulation 
Temperature, 
 solvent used 
 
3  Kneading  Time Mixing time and  
speed 
Impeller speed : (slow/medium/high)  
Chopper speed: (slow/medium/high)  
Depending up on the formulation. 
Impeller speed &  
chopper speed 
4  Drying  Inlet/outlet  
temperature & time 
Inlet/outlet  
temperature &  
Drying time 
Initial drying:………. C  
Drying time: ……………min.  
Final drying: …… 
0C±50C  
Loss on drying : ……….% below 3% or 
depending  
on formulation 
5  Lubrication  Time Mixing time and  
speed 
Mixing time: ……………min.  
Speed: slow….rpm.  
Content uniformity:  
Physical parameters – for information. 
Blender/granulator  
speed 
6  Compression  Pressure and turret  Machine speed and  Average weight: mg±5%, 7.5%, 10%.  
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speed compression  
pressure 
Uniformity of weight mg :   
Thickness : ………….mm  
Hardness : …………..KN or Kg/cm2 
 Disintegration time: NMT…..min.  
Friability : NMT…………%w/w  
Assay : As per the label claim  
Dissolution… % 
7  Coating Pan speed and 
spray  
rate 
Pan speed  
Inlet & outlet  
temperature  
Spray rate 
Average weight:....mg±5%  
Weight of 20 tablets: ….…..mg  
Thickness : ………….mm  
Disintegration time: NMT…..min.  
Assay : As per the label claim  
Dissolution: ………….  
 
 
Conclusion 
Process validation is major requirement of cGMPs 
regulation for the process efficiency and sturdiness 
from the review validation data on pharmaceutical 
process validation and process control variables of 
tablets manufacturing processes in industry and it is the 
full fledged quality attributing tool for the 
pharmaceutical industries. The main goal in qualifying 
laboratory equipment is to ensure the validity of data. 
The current equipment qualification programs and 
procedures used within the pharmaceutical industry are 
based on regulatory requirements, voluntary 
standards,vendor practices, and industry practices. 
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